课题基金 / 基金详情

Novel lymphatic genes that regulate heart valve development and disease

Novel lymphatic genes that regulate heart valve development and disease
调节心脏瓣膜发育和疾病的新型淋巴基因
批准号:
10585707
负责人:
Rajanarayanan S Srinivasan
金额:
$56.27万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-12-15 至 2026-11-30

项目摘要

项目成果

Rajanarayanan S Srinivasan的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Valves are present within hearts, veins and lymphatic vessels to regulate the flow of blood and lymph. Defects in the development or functioning of valves could lead to diseases such as lymphedema and degenerative heart valve disease. Venous and lymphatic (vascular) valves are composed of two layers of endothelial cells with a thin layer of collagen-rich extra cellular matrix (ECM). Few if any interstitial cells are observed within vascular valves. In contrast, cardiac valves are made of two major cell types: numerous ECM producing valvular interstitial cells (VICs), which are surrounded by a single layer of valvular endothelial cells (VECs). Despite significant differences in their structure and the mechanical force that they experience, cardiac and vascular valves share interesting similarities. The homeobox transcription factor PROX1 is necessary for the development of vascular valves. PROX1 is also expressed in a subset of VECs on the downstream side of heart valves. We have now determined that the deletion of PROX1 from VECs results in the accumulation of proteoglycans and the consequent thickening of heart valves. Thus, PROX1 in VECs regulates the development and functioning of VICs through yet unknown mechanisms. Building on our preliminary data we will test our Central Hypothesis that a previously unknown PROX1àFOXC2àPDGF-B signaling pathway from downstream VECs regulates VIC identity and, in turn, the ECM composition of valves. Abnormally high synthesis of proteoglycans is observed in several valve disorders. Valve defects are observed in ~8% in individuals >65 years old and ~13% in those who are >75. Pharmacological approaches to treat these valve defects do not exist. Hence, the outcomes of our proposed research are expected to be significant because they will substantially advance our insight into the molecular and cellular mechanisms of VEC-VIC crosstalk during cardiac valve development and shed light on potential therapeutic strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the Mechanisms of Lymphatic Vascular Growth and Function
Defining the Mechanisms of Lymphatic Vascular Growth and Function
Defining the mechanisms of lymphatic and lymphovenous valve development
海外基金